BAUDETTE, Minn., Oct. 13, 2015 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) announced today the
appointment of Peter A. Lankau to
the Company's Board of Directors to fill the existing vacancy in
the Board. Mr. Lankau has over 30 years of management
experience in developing and commercializing pharmaceutical
products.
Mr. Lankau is a principal in the consulting firm, Lankau
Consulting LLC, which provides advisory and consulting services to
support boards of directors and senior management of pharmaceutical
and biotechnology companies, as well as venture capital and private
equity firms. He is Chairman of the Board of Phosphagenics
Limited, an Australian research-based biotechnology company.
Prior to that, Mr. Lankau was Executive Chairman at Nautilus
Neurosciences, Inc., a private neurology-focused specialty
pharmaceutical company. Prior to Nautilus, Mr. Lankau was
Chairman and CEO of Logical Therapeutics, Inc., a venture backed,
development stage biopharmaceutical company, and was President,
Chief Executive Officer and Director of Endo Pharmaceuticals Inc.,
a publicly traded specialty pharmaceutical company. Mr. Lankau also
currently serves on the Board of Advisors of Orchard Venture
Partners, a life sciences venture capital firm.
Robert E. Brown, Jr., Chairman of
ANI, commented: "We are delighted that Peter Lankau has joined the ANI Board of
Directors. Peter's broad and deep experience in the specialty
pharmaceutical industry makes him an ideal fit for ANI. We very
much look forward to working with Peter as we continue to grow the
Company."
Mr. Lankau added, "I am excited to join the Board of Directors
of ANI Pharmaceuticals at a time when ANI is embarking on a
significant expansion of its business prospects with new and
innovative approaches to its generic and specialty business. I have
been impressed with ANI's Board of Directors and management team
and the focus on growth they all share. I believe my experience in
developing and commercializing specialty and generic
pharmaceuticals will add to the already robust expertise within the
company and I look forward to contributing to the team."
Mr. Lankau will serve on ANI's Compensation Committee and
Corporate Governance and Nominating Committee. Following Mr.
Lankau's appointment, the Company's Board of Directors is comprised
of a majority of independent directors and the Company meets the
independent director requirements set forth in Nasdaq Listing Rule
5605.
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an
integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription
pharmaceuticals. The Company's targeted areas of product
development currently include narcotics, oncolytics (anti-cancers),
hormones and steroids, and complex formulations involving extended
release and combination products. For more information, please
visit our website www.anipharmaceuticals.com.
Forward Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about price increases, the Company's future
operations, products financial position, operating results and
prospects, the Company's pipeline or potential markets therefore,
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "plans," "potential," "future," "believes,"
"intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Information on risks and
uncertainties are described in the Company's filings with the
Securities and Exchange Commission, including its most recent
annual report on Form 10-K and quarterly reports on Form 10-Q, as
well as its proxy statement. All forward-looking statements in this
news release speak only as of the date of this news release and are
based on the Company's current beliefs, assumptions, and
expectations. The Company undertakes no obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ani-pharmaceuticals-appoints-peter-a-lankau-to-its-board-of-directors-300158188.html
SOURCE ANI Pharmaceuticals, Inc.